EDGEMOND JAMES sold $260K of UTHR
EDGEMOND JAMES (CFO AND TREASURER) sold 480 shares of UNITED THERAPEUTICS Corp (UTHR) at $541.14 ($0.26M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides transparency on insider liquidity but, with 10b5-1, usually carries limited incremental fundamental information.
Market read
A disclosed insider sale in UTHR; likely not a standalone catalyst given the stated 10b5-1 plan.
What to watch
Check whether there are multiple recent insider sales in the same window or changes in planned selling size/pace; one Form 4 alone is often insufficient.
Background
This is a SEC Form 4 insider transaction (officer sale) for United Therapeutics, executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
United Therapeutics CFO and treasurer Edgemond James sold $259,748 of UTHR shares via a Rule 10b5-1 plan on June 4.
Likely limited near-term impact; any reaction should be muted unless accompanied by other company-specific negative news.
The filing is an ownership-change disclosure with a stated 10b5-1 plan, which reduces the likelihood of immediate, discretionary information content.
Market effects
Minimal; this is company-specific insider activity without sector-wide catalyst.
None expected beyond routine US biotech tape noise.
Low; Form 4 insider transactions are not typically globally market-moving.
Counterpoint
Because the sale is under a 10b5-1 plan, traders may overreact less than usual; any dip could be more about positioning than information.
Key entities
- issuerUnited Therapeutics Corp
Subject of the Form 4 insider sale by CFO and treasurer Edgemond James.
- insiderEdgemond James
CFO and treasurer who sold 480 shares at $541.1433 on 2026-06-04.
